Cargando…

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Risankizumab (Skyrizi(®); risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate...

Descripción completa

Detalles Bibliográficos
Autor principal: Blair, Hannah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475056/
https://www.ncbi.nlm.nih.gov/pubmed/32632826
http://dx.doi.org/10.1007/s40265-020-01357-1

Ejemplares similares